Trial reportBMC ophthalmology2025
Efficacy and safety of prophylactic simultaneous intravitreal moxifloxacin injection with standard intravitreal anti-VEGF injection procedure in cases of cystoid macular edema and macular neovascularization.
Trial report in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the safety and efficacy of prophylactic use of commercially available intravitreal moxifloxacin 0.5% (Vigamox) at the time of intravitreal anti-VEGF injection against post-injection infectious endophthalmitis. PATIENTS AND
methodsA prospective interventional randomized controlled trial including eyes with cystoid macular edema or macular neovascularization planned to receive intravitreal anti-VEGF therapy. Eyes were randomly assigned to either day A or day B for intravitreal injection procedure; eyes in day A received simultaneous intravitreal anti-VEGF and moxifloxacin (study group), while eyes in day B received intravitreal anti-VEGF only (control group). The presence of postoperative toxic reactions and endophthalmitis rates was assessed together with change in BCVA & retinal in both groups.
resultsA total of 1352 intravitreal injection procedures were done in study group and 1487 in control group. Endophthalmitis was rare across both groups, 0 case in the study group and two cases (0.2%) in the control group which was statistically insignificant (P = 0.502). Reduction in CME was comparable in both groups, (MD = -228.17 μm) in the study group, (MD = -221.28 μm) in the control group (P = 0.044). Similar Improvement of BCVA in both groups with a difference of -0.56 in the study group and - 0.54 in the control group (P = 0.151). No toxic AC reactions or retinal toxicity was observed in the study group confirmed by similar postoperative ellipsoid zone/external limiting membrane (EZ/ELM) improvement compared to control group, 37.0% and 27.0% respectively.
conclusionSimultaneous intravitreal injection of moxifloxacin during intravitreal anti-VEGF procedure is safe and effective measure to be added to the armamentarium of prophylaxis against post injection endophthalmitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.